Cargando…

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab

BACKGROUND: Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. OBJECTIVES: To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: van Muijen, Marloes E., Atalay, S., van Vugt, L. J., Vandermaesen, L. M. D., van den Reek, J. M. P. A., de Jong, E. M. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128951/
https://www.ncbi.nlm.nih.gov/pubmed/33778926
http://dx.doi.org/10.1007/s40801-021-00227-w
_version_ 1783694205554524160
author van Muijen, Marloes E.
Atalay, S.
van Vugt, L. J.
Vandermaesen, L. M. D.
van den Reek, J. M. P. A.
de Jong, E. M. G. J.
author_facet van Muijen, Marloes E.
Atalay, S.
van Vugt, L. J.
Vandermaesen, L. M. D.
van den Reek, J. M. P. A.
de Jong, E. M. G. J.
author_sort van Muijen, Marloes E.
collection PubMed
description BACKGROUND: Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. OBJECTIVES: To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab. METHODS: Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire (PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy. RESULTS: Sixty-five patients were included. ‘To be free of itching’, ‘to be healed of all skin defects’ and ‘to have confidence in the therapy’ were rated quite/very important in 78.5% of the patients, followed by ‘to have no fear the disease will progress’ (75.4%) and ‘to get better skin quickly’ (75.4%). Goals related to the subscale ‘confidence in healing’ were still of high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was significantly more important than for males to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’. CONCLUSIONS: Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-021-00227-w.
format Online
Article
Text
id pubmed-8128951
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81289512021-05-27 Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab van Muijen, Marloes E. Atalay, S. van Vugt, L. J. Vandermaesen, L. M. D. van den Reek, J. M. P. A. de Jong, E. M. G. J. Drugs Real World Outcomes Original Research Article BACKGROUND: Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. OBJECTIVES: To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab. METHODS: Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire (PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy. RESULTS: Sixty-five patients were included. ‘To be free of itching’, ‘to be healed of all skin defects’ and ‘to have confidence in the therapy’ were rated quite/very important in 78.5% of the patients, followed by ‘to have no fear the disease will progress’ (75.4%) and ‘to get better skin quickly’ (75.4%). Goals related to the subscale ‘confidence in healing’ were still of high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was significantly more important than for males to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’. CONCLUSIONS: Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-021-00227-w. Springer International Publishing 2021-03-28 /pmc/articles/PMC8128951/ /pubmed/33778926 http://dx.doi.org/10.1007/s40801-021-00227-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
van Muijen, Marloes E.
Atalay, S.
van Vugt, L. J.
Vandermaesen, L. M. D.
van den Reek, J. M. P. A.
de Jong, E. M. G. J.
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title_full Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title_fullStr Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title_full_unstemmed Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title_short Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
title_sort unmet personal patient needs in psoriasis patients with low disease activity on adalimumab, etanercept or ustekinumab
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128951/
https://www.ncbi.nlm.nih.gov/pubmed/33778926
http://dx.doi.org/10.1007/s40801-021-00227-w
work_keys_str_mv AT vanmuijenmarloese unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab
AT atalays unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab
AT vanvugtlj unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab
AT vandermaesenlmd unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab
AT vandenreekjmpa unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab
AT dejongemgj unmetpersonalpatientneedsinpsoriasispatientswithlowdiseaseactivityonadalimumabetanerceptorustekinumab